GSK to License Arrowhead’s RNAi Therapeutic for Liver Disease in $1 Billion Deal

By PacConAdmin | November 23, 2021

GlaxoSmithKline (GSK) has forged an exclusive license agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic currently in a phase 1/2 trial. The deal is potentially worth more than $1 billion.
Source: Drug Industry Daily

Posted in Drug Industry Daily